Testosterone Therapy Drugs
Testosterone therapy drugs are advertised as effective in treating low testosterone, a condition that has been linked to causing loss of interest in sex, difficulty getting an erection, and tiredness and lack of energy to name a few. Multiple studies have revealed that not only are the drugs ineffective in treating such conditions, but also that the drugs can cause an increased risk of heart attack, stroke, and/or pulmonary embolism.
In June 2014, the FDA began requiring manufacturers of testosterone products to warn that their drug may cause a risk of blood clot in the veins. In 2015, the FDA required the manufacturers to again update their labels to warn of increased risk of heart attack and stroke.
At this time, GoldenbergLaw is no longer accepting new testosterone therapy drug cases.
Case Quick Facts
Testosterone therapy drugs were indicated by the FDA for treatment of the medical condition, hypogonadism, or low testosterone. Low testosterone (Low-T) is a disease where the body is unable to produce a normal amount of testosterone. Low-T has been linked to increased body fat, lethargy, poor erectile function, lowered sex drive, and reduced muscle mass.
Testosterone levels in the body, however, also naturally decline with age. Testosterone therapy drug makers have pushed the drug to treat Low-T, even in men who may be experiencing naturally declining testosterone levels. The drug makers have taken in billions annually from sales of their drugs.
Testosterone therapy drugs have been over promoted, are proven ineffective, and further cause dangerous medical events of heart attack, stroke and pulmonary embolism.
In 2014, the FDA began issuing alerts to healthcare providers requesting the report any side effects arising from these testosterone therapy products. It also indicated it was evaluating the medications for heart risks. That same year, it required the makers of testosterone therapy medications to warn of increased risk of blood clots. In 2015 the FDA required all testosterone therapy replacement manufacturers to warn of increased risk of:
- Heart attack
- Pulmonary embolism
There are many different types of testosterone therapy medication on the U.S. market produced by a number of different manufacturers. Some of these manufacturers include: Abbvie Inc., Abbott Laboratories, and Watson Laboratories.
Currently, a litigation against the above-listed manufacturers of testosterone therapy is ongoing in the Northern District of Illinois. All of the cases have been consolidated there, in what is called a multidistrict litigation (MDL). Recently, the first full trial against Abbvie, the maker of the testosterone therapy medication Androgel, resulted in a jury verdict against Abbvie for $150 million for falsely advertising the therapy medication. Many more cases are scheduled to be tried in the MDL over the next year. If you want to get your case heard and file a testosterone lawsuit, our team is the firm for you.
GoldenbergLaw is no longer accepting new testosterone therapy drug cases.
Studies and Reports
In 2010, a study by The New England Journal of Medicine followed a group of 209 men with an average age of 74 years. They found that the group that took the testosterone gel had higher rates of adverse events than the group that did not take the drug. Although the study was limited in sample size and diversity of participants, researchers were able to conclude that the application of a testosterone gel was associated with an increased risk of cardiovascular adverse events.
Studies and Reports
Another recent publication came from the Journal of the American Medical Association (JAMA) in November 2013. This study suggested men taking TT were at a 30 percent increased risk of stroke, heart attack and death.
Studies and Reports
In January 2014, a cohort study published in PLOS ONE assessed the risk of acute non-fatal myocardial infarction (heart attack) following an initial TT prescription. Researchers found a twofold increase in the risk of heart attack among men aged 65 years and older in the first 90 days of taking testosterone therapy. In men 65 years and younger with a pre-existing history of heart disease, the risk was two to threefold. The study did not find an increased risk among younger men who did not have pre-existing heart conditions.
Why Choose GoldenbergLaw?
If you find yourself in the middle of a testosterone therapy lawsuit, look no further than GoldenbergLaw. GoldenbergLaw has a wide array of experience when it comes to drug-related issues and lawsuits. Our team of testosterone therapy lawyers will make sure that your case is handled with care.